Email bulletin archive

Archive

December 2015

• Access to hepatitis C treatment in Europe
• Treatment costs
• Cost of generic direct-acting antivirals
• Coffee and liver fibrosis
• Liver transplant waiting list reductions
• Shortening treatment time
• Is this your copy of the infohep news bulletin?

November 2015

• News from The Liver Meeting 2015, San Francisco
• Access to hepatitis C treatment in the United States: doctors and federal government urge wider access
• Long-term outcomes after hepatitis C treatment: liver cancer
• Long-term outcomes after hepatitis C treatment: reversal of liver damage
• Hepatitis C treatment for people who inject drugs
• Treatment for genotype 3
• New drugs: pan-genotypic treatment combinations
• Daclatasvir licensed to Medicines Patent Pool
• Sofosbuvir and bradycardia
• World Hepatitis Summit report and resources
• New hepatitis C treatment factsheet
• Is this your copy of the infohep news bulletin?

October 2015

• US guidelines updated to recommend hepatitis C treatment for all
• US Food and Drug Administration warning on Viekira Pak and Technivie
• Hepatitis C treatment and prevention in people who inject drugs
• Consensus definition for late presentation of viral hepatitis in Europe
• Hepatic encephalopathy
• Is this your copy of the infohep news bulletin?

September 2015

• World Hepatitis Summit 2015
• Gilead releases preliminary results on new pan-genotypic combination
• Hepatitis C and heart disease
• Daklinza approval for genotype 3 in European Union
• Interferon-free treatment for people with HIV and HCV co-infection
• The 24th International Harm Reduction Conference
• Is this your copy of the infohep news bulletin?

July 2015

• Hepatitis C in sub-Saharan Africa
• Ribavirin
• AbbVie reports on long-term post-cure outcomes of hepatitis C treatment
• UK treatment access
• Liver transplantation in HIV and hepatitis C co-infection
• New booklets from the London Joint Working Group on Substance Use & Hepatitis C and Dr Harris, LSHTM
• Is this your copy of the infohep news bulletin?

June 2015

• More news from the International Liver Congress 2015
• Hepatitis B news
• Hepatitis delta
• Statins and cirrhosis
• Hepatitis C and cancer
• Hepatitis C treatment
• Access to treatment
• Hepatitis C treatment factsheets
• Is this your copy of the infohep news bulletin?

May 2015

• News from the International Liver Congress 2015
• Hepatitis C special population: Chronic kidney disease
• Treatment-experienced people
• Decompensated cirrhosis, advanced cirrhosis and transplant patients
• Genotype 3
• Previously untreated people
• EASL guidelines on treatment of hepatitis C
• When to treat and liver damage in undiagnosed people
• Alcohol and liver disease in people with hepatitis C
• Hepatitis C treatment factsheets
• Is this your copy of the infohep news bulletin?

March 2015

• World Health Organization hepatitis B treatment guidelines
• Risks of delaying HCV treatment in HIV/HCV co-infection
• Interferon-free treatment for HIV/HCV co-infection
• Adherence to hepatitis C treatment
• Sofosbuvir access
• UNITAID
• Harvoni recommended for genotypes 1 and 4 in England
• 24th International Harm Reduction Conference – call for papers
• Hepatitis C treatment factsheets
• Is this your copy of the infohep news bulletin?

February 2015

• Hepatitis B treatment
• Cost of hepatitis C treatment
• Activist guide to treatment access
• UNITAID guide to detection and monitoring of hepatitis C
• Merck delay
• 24th International Harm Reduction Conference – call for papers
• Hepatitis C treatment factsheets
• Is this your copy of the infohep news bulletin?

January 2015

• European approval for AbbVie interferon-free combination
• Cost of treatment
• Hepatitis C treatment availability: United Kingdom
• India: Sofosbuvir patent rejected
• Hepatitis C treatment for people after liver transplant
• Hepatitis C drugs in development
• Hepatitis C treatment factsheets
• Is this your copy of the infohep news bulletin?